In fiscal 2026, which ended Apr 30, 2026, Alzamend Neuro, Inc. used $8.1 million of cash from operations, down 22.8% from the year before.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2027
Jul 31, 2026
|
FY 2026
Apr 30, 2026
|
FY 2025
Apr 30, 2025
|
FY 2024
Apr 30, 2024
|
FY 2023
Apr 30, 2023
|
FY 2022
Apr 30, 2022
|
FY 2021
Apr 30, 2021
|
|---|---|---|---|---|---|---|---|
| Operating | |||||||
| Depreciation and amortization |
0
|
0
+118.2%
|
0
+0.0%
|
0
+120.0%
|
0
+549.9%
|
0
|
—
|
| Stock-based compensation |
1
|
1
+117.6%
|
0
-66.0%
|
1
-73.3%
|
4
-18.7%
|
4
+116.9%
|
2
|
| Operating cash flow |
-7
|
-8
-22.8%
|
-7
+20.6%
|
-8
+7.3%
|
-9
-34.9%
|
-7
-143.9%
|
-3
|
| Investing | |||||||
| Investing cash flow |
—
|
—
|
-0
-103.7%
|
-0
-38.3%
|
—
|
-0
-205.5%
|
0
|
| Financing | |||||||
| Short-term debt issued |
—
|
—
|
—
|
—
|
—
|
—
|
2
|
| Financing cash flow |
9
|
5
-53.7%
|
10
+185.9%
|
4
+1826112.5%
|
0
-100.0%
|
19
+323.7%
|
4
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALZN (Nasdaq)
- Fiscal year ends
- April 30
- Incorporated in
- DE
- Headquarters
- Atlanta, GA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1677077
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.